A

    Atrium Therapeutics, Inc. Common Stock (RNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.32
    -0.32 (-2.35%)

    Market Cap: $233.32M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(14/26)
    Avg Surprise
    -11.32%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.67
    Range$-0.67 - $-0.67
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-0.70-4.5%
    7d ago$-0.70-4.5%
    Current$-0.67
    Revenue Consensus
    $11M
    Range$0 - $15M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.19
    Range$-2.19 - $-2.19
    1 analysts
    Revenue Consensus
    $21M
    Range$9M - $26M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.19---
    Sep 26EST
    		-$-0.67---
    Jun 26
    Reported Aug 13
    		$-1.18$-0.64-84.38%Miss+2.5%
    Mar 26
    Reported May 14
    		$-0.97$-1.05+7.62%Beat-7.8%
    Dec 25
    Reported Feb 26
    		$-1.59$-1.26-26.19%Miss-98.8%
    Sep 25
    Reported Nov 10
    		$-1.27$-1.10-15.45%Miss-95.4%
    Jun 25
    Reported Aug 7
    		$-1.21$-0.96-26.04%Miss-86.2%
    Mar 25
    Reported May 8
    		$-0.90$-0.88-2.27%Miss-13.9%
    Dec 24
    Reported Feb 26
    		$-0.80$-0.78-2.45%Miss-1.3%
    Sep 24
    Reported Nov 7
    		$-0.65$-0.72+9.72%Beat+8.5%
    Jun 24
    Reported Aug 9
    		$-0.65$-0.78+16.67%Beat+1.5%
    Mar 24
    Reported May 9
    		$-0.79$-0.88+10.23%Beat-6.8%
    Dec 23
    Reported Feb 28
    		$-0.79$-0.66-19.70%Miss+10.2%
    Sep 23
    Reported Nov 8
    		$-0.71$-0.75+5.33%Beat+13.4%
    Jun 23
    Reported Aug 8
    		$-0.66$-0.79+16.46%Beat+28.3%
    Mar 23
    Reported May 9
    		$-0.74$-0.86+13.95%Beat-4.2%
    Dec 22
    Reported Feb 28
    		$-0.88$-0.89+1.12%Beat-7.3%
    Sep 22
    Reported Nov 8
    		$-0.82$-0.93+11.83%Beat-20.6%
    Jun 22
    Reported Aug 9
    		$-0.92$-0.77-19.48%Miss-31.4%
    Mar 22
    Reported May 10
    		$-0.71$-0.83+14.46%Beat-10.9%
    Dec 21
    Reported Mar 1
    		$-0.82$-0.70-17.14%Miss-90.7%
    Sep 21
    Reported Nov 9
    		$-0.68$-0.68+0.00%Beat-119.4%
    Jun 21
    Reported Aug 9
    		$-0.70$-0.71+1.41%Beat+43.1%
    Mar 21
    Reported May 12
    		$-0.64$-0.56-14.29%Miss-14.3%
    Dec 20
    Reported Mar 15
    		$-0.43$-0.34-26.47%Miss-
    Sep 20
    Reported Nov 10
    		$-0.31$-0.43+27.91%Beat-
    Jun 20
    Reported Aug 10
    		$-1.23$-0.36-241.67%Miss-
    Mar 20
    Reported Jun 8
    		$-0.56N/A+64.56%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.66EV/EBITDA-5.72x
    Price/FCF-1.05xFCF Yield-95.41%
    Profitability
    Profit Margin-184.10%Operating Margin-753.00%
    ROE-44.00%ROIC-121.03%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio8.73xQuick Ratio8.73x
    Trading Statistics
    Beta0.93Avg Volume150.97K
    52-Week High$16.7752-Week Low$11.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.56
    SMA 20$12.91
    SMA 50$12.62
    SMA 200$34.33
    EMA 10$13.44
    EMA 20$13.08
    EMA 50$13.11
    EMA 200$25.16

    MACD

    Line: 0.41Signal: 0.33Hist: 0.08

    ADX

    ADX: 34.1+DI: 24.3-DI: 15.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$14.09

    Bollinger Bands

    Upper Band$14.46
    Lower Band$11.36
    %B Position2404%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    55.6

    Momentum Oscillators

    Stoch %K78.5
    Stoch %D86.6
    Williams %R-37.4
    ROC (10d)2.8%
    Momentum0.36
    CCI (20d)45.7
    MFI (14d)74.9

    Volatility Measures

    ATR (14d)$0.50(3.8%)
    StdDev (20d)0.78
    Hist Vol38.6%(Moderate)

    Volume Flow

    VWAP$13.32
    OBV87.3M
    AD Line-7.8K
    CMF (20d)0.184

    Volume Metrics

    Avg Vol (20d)153.9K
    Vol Ratio0.6x
    VWMA (20d)$13.00

    Pivot Points

    R3$14.33
    R2$14.14
    R1$13.89
    Pivot Point$13.70
    S1$13.45
    S2$13.26
    S3$13.01

    Advanced Oscillators

    TSI23.35
    Ultimate Osc61.4
    KST108.69

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.00M$19.64M$859,000$12.47M$3.85M$1.57M$2.97M$2.34M$2.04M$3.54M$2.19M$2.82M
    Cost of Revenue$343,000$151,000$1.50MN/A$138.13MN/A$738,000$710,000$687,000$641,000$615,000$47.71M
    Gross Profit$2.66M$19.48M$859,000$12.47M$-134,278,000$1.57M$2.97M$2.34M$1.36M$2.90M$1.58M$-44,896,000
    Operating Expenses$25.28M$36.76M$48.89M$201.28M$36.86M$133.09M$123.96M$100.47M$83.98M$80.09M$68.32M$13.73M
    R&D$15.34M$16.66M$18.50M$154.95M$138.13M$99.49M$95.63M$77.20M$63.94M$66.83M$52.82M$47.71M
    SG&A$0$20.26M$30.40M$46.33M$36.86M$33.60M$28.34M$23.27M$20.73M$13.90M$16.12M$13.73M
    Operating Income$-22,618,000$-17,280,000$-48,035,000$-188,806,000$-171,142,000$-131,517,000$-120,990,000$-98,134,000$-82,626,000$-77,187,000$-66,743,000$-58,625,000
    Interest Income$0$0$0$14.74M$14.48M$16.18M$18.53M$17.97M$11.95M$8.43M$6.41M$6.28M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$391,000$0
    Income Before Tax$-20,186,000$-16,633,000$-48,035,000$-174,442,000$-157,315,000$-115,773,000$-102,257,000$-80,398,000$-70,793,000$-68,855,000$-60,443,000$-52,358,000
    Income Tax Expense$0$0$34,000$0$0$0$0$0$0$597,724$-1$-6,280,000
    Net Income$-20,186,000$-16,633,000$-48,069,000$-174,442,000$-157,315,000$-115,773,000$-102,257,000$-80,398,000$-70,793,000$-68,855,000$-60,443,000$-52,358,000
    EBITDA$-22,275,000$-16,482,000$-47,913,000$-173,386,000$-170,328,000$-130,732,000$-120,252,000$-97,424,000$-81,939,000$-76,546,000$-66,128,000$-58,059,000
    EBIT$-22,618,000$-16,633,000$-48,035,000$-174,442,000$-171,142,000$-131,517,000$-120,990,000$-98,134,000$-82,626,000$-77,187,000$-66,743,000$-58,625,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RNA

    News

    A new Atrium hire gets options on 11,000 shares and 5,500 restricted units

    Atrium Therapeutics (Nasdaq: RNA) granted equity inducement awards to a new non-executive employee on August 20, 2026. The awards include non-qualified options for 11,000 shares at an exercise price of $13.48 and 5,500 restricted stock units, both with multi-year time-based vesting schedules. These grants were approved by the board's independent Human Capital Management Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

    Stock Titan•8/20/26•
    Somewhat-Bullish

    Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership

    RA Capital Management, L.P., and its affiliates, including Peter Kolchinsky and Rajeev Shah, have filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Atrium Therapeutics (RNA) common stock as of June 30, 2026. This indicates they hold no shares and possess no voting or dispositive power over Atrium Therapeutics stock, falling below the 5% ownership threshold. The filing confirms that each reporting person now owns 5 percent or less of the common stock.

    Stock Titan•8/14/26•
    Somewhat-Bearish

    Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com

    This article reports on the filing of a Form 8K by Atrium Therapeutics Inc. for August 13. The brief notice highlights this corporate action as reported by Investing.com, a financial markets news service. No further details about the content of the Form 8K are provided within the article.

    Investing.com Canada•8/14/26•
    Neutral

    Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds

    Sessa Capital IM, L.P. and John Petry have reported a beneficial ownership of 1,500,000 shares of Atrium Therapeutics, Inc. common stock, which accounts for 8.8% of the outstanding shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment. The shares are held by Sessa funds managed by Sessa Capital IM, L.P., with Sessa Capital (Master), L.P. having rights to dividends or sale proceeds from over 5% of the common stock.

    Stock Titan•8/14/26•
    Neutral

    T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A

    T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1,472,984 shares in Atrium Therapeutics Inc., which constitutes an 8.6% stake in the company. The filing indicates that T. Rowe Price Associates holds sole voting power over 1,472,772 shares and sole dispositive power over all 1,472,984 shares, with no shared voting or dispositive powers. Despite the disclosure, the firm explicitly denies beneficial ownership of these securities.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About RNA

    Does RNA pay dividends?
    Atrium Therapeutics, Inc. Common Stock (RNA) does not currently pay a regular dividend.
    What is RNA's market cap?
    Atrium Therapeutics, Inc. Common Stock (RNA) has a market capitalization of $233.32M with a current stock price of $13.32.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In